Enovis (NYSE:ENOV) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Enovis (NYSE:ENOV) announced its earnings results on Wednesday. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06, Zacks reports. The firm had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis updated its FY 2025 guidance to 3.100-3.250 EPS.

Enovis Stock Down 4.9 %

Enovis stock opened at $40.03 on Thursday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $2.28 billion, a PE ratio of -18.28 and a beta of 1.94. The firm’s fifty day moving average is $44.90 and its 200 day moving average is $44.34. Enovis has a 12-month low of $38.27 and a 12-month high of $63.96.

Analyst Ratings Changes

Separately, Needham & Company LLC decreased their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.